Akebia Therapeutics, Inc. (AKBA)Â
Largest Insider Buys in Sector
AKBA Stock Price History Chart
AKBA Stock Performance
About Akebia Therapeutics, Inc.
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsuka Pharmaceutical Co. Ltd. for the development and commercialization of vadadustat in the United States, the European Union, Russia, China, Australia, Canada, the Middle East, and other countries; and Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
Insider Activity of Akebia Therapeutics, Inc.
Over the last 12 months, insiders at Akebia Therapeutics, Inc. have bought $0 and sold $383,681 worth of Akebia Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Akebia Therapeutics, Inc. have bought $0 and sold $422,978 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 100,000 shares for transaction amount of $344,000 was made by Butler John P. (CEO and President) on 2019‑11‑20.
List of Insider Buy and Sell Transactions, Akebia Therapeutics, Inc.
| 2024-05-13 | Sale | SVP, Chief Operating Officer | 34,840 0.0162% | $1.26 | $43,898 | +9.38% | ||
| 2024-05-13 | Sale | SVP, Chief Legal Officer | 12,016 0.0056% | $1.26 | $15,140 | +9.38% | ||
| 2024-02-29 | Sale | CEO and President | 46,570 0.0249% | $1.58 | $73,581 | -9.87% | ||
| 2024-02-29 | Sale | SVP, Chief Operating Officer | 8,661 0.0046% | $1.58 | $13,684 | -9.87% | ||
| 2024-02-29 | Sale | SVP, Chief Medical Officer | 7,169 0.0038% | $1.58 | $11,327 | -9.87% | ||
| 2024-02-29 | Sale | SVP, Chief Legal Officer | 5,974 0.0032% | $1.58 | $9,439 | -9.87% | ||
| 2024-02-27 | Sale | CEO and President | 37,733 0.0186% | $1.52 | $57,354 | -13.41% | ||
| 2024-02-27 | Sale | SVP, Chief Operating Officer | 10,744 0.0053% | $1.52 | $16,331 | -13.41% | ||
| 2024-02-27 | Sale | SVP, Chief Medical Officer | 8,367 0.0041% | $1.52 | $12,718 | -13.41% | ||
| 2024-02-27 | Sale | SVP, Chief Legal Officer | 7,411 0.0036% | $1.52 | $11,265 | -13.41% | ||
| 2024-02-01 | Sale | CEO and President | 46,489 0.0254% | $1.68 | $78,102 | -15.79% | ||
| 2024-02-01 | Sale | SVP, Chief Medical Officer | 24,311 0.0133% | $1.68 | $40,842 | -15.79% | ||
| 2023-08-25 | Sale | SVP, Chief Medical Officer | 27,000 0.0145% | $1.15 | $31,050 | +9.13% | ||
| 2023-05-25 | Sale | SVP, Chief Operating Officer | 95,478 0.0522% | $1.22 | $116,760 | +3.31% | ||
| 2023-05-25 | Sale | SVP, Chief Legal Officer | 63,186 0.0346% | $1.22 | $77,270 | +3.31% | ||
| 2023-05-16 | Sale | SVP, Chief Medical Officer | 63,567 0.035% | $1.07 | $67,890 | +20.00% | ||
| 2023-05-16 | Sale | SVP, CFO and Treasurer | 63,567 0.035% | $1.07 | $67,890 | +20.00% | ||
| 2023-03-01 | Sale | CEO and President | 91,868 0.0482% | $0.88 | $80,614 | +23.50% | ||
| 2023-03-01 | Sale | SVP, Chief Medical Officer | 14,123 0.0074% | $0.88 | $12,393 | +23.50% | ||
| 2023-03-01 | Sale | SVP, CFO and Treasurer | 7,210 0.0038% | $0.88 | $6,327 | +23.50% |
Insider Historical Profitability
| Butler John P. | CEO and President | 2044580 0.9371% | $2.07 | 6 | 9 | <0.0001% |
| Burke Steven Keith | SVP, Chief Medical Officer | 695840 0.3189% | $2.07 | 1 | 13 | |
| Dahan Michel | SVP, Chief Operating Officer | 672092 0.308% | $2.07 | 0 | 20 | |
| Hadas Nicole R. | SVP, Chief Legal Officer | 651243 0.2985% | $2.07 | 1 | 23 | +3.18% |
| Satter Muneer A | director | 3037042 1.392% | $2.07 | 13 | 0 | <0.0001% |
| Novo A/S | 10 percent owner | 1516387 0.695% | $2.07 | 1 | 0 | +3.18% |
| Spellman David A | SVP, CFO and Treasurer | 446483 0.2046% | $2.07 | 0 | 6 | |
| Novartis Bioventures Ltd | 10 percent owner | 182590 0.0837% | $2.07 | 1 | 0 | +3.18% |
| Faulkingham Dell | SVP, CCO | 173841 0.0797% | $2.07 | 0 | 5 | |
| Amello Jason | SVP, CFO & Treasurer | 144642 0.0663% | $2.07 | 2 | 1 | <0.0001% |
| Tubridy Karen L | SVP, Chief Development Officer | 84679 0.0388% | $2.07 | 0 | 1 | |
| ADAMS ADRIAN | director | 63700 0.0292% | $2.07 | 1 | 0 | |
| GILMAN STEVEN C | 43430 0.0199% | $2.07 | 1 | 3 | ||
| Smith Cynthia | director | 37833 0.0173% | $2.07 | 1 | 1 | |
| Cotreau Violetta | SVP, Chief Accounting Officer | 29121 0.0133% | $2.07 | 0 | 2 | |
| GOWEN MAXINE | director | 24133 0.0111% | $2.07 | 1 | 1 | <0.0001% |
| Nash Duane | director | 21499 0.0099% | $2.07 | 0 | 14 | |
| Renaud Ronald C JR | director | 5000 0.0023% | $2.07 | 1 | 0 | <0.0001% |
| WYZGA MICHAEL S | director | 1500 0.0007% | $2.07 | 1 | 0 | +3.18% |
Institutional Investor Ownership
| Alerce Investment Management L P | $24.17M | 6.3 | 13.21M | -18.51% | -$5.49M | 0.28 | |
| The Vanguard Group | $15.05M | 3.93 | 8.23M | +8.13% | +$1.13M | <0.0001 | |
| Acadian Asset Management | $9.71M | 2.53 | 5.31M | -23.22% | -$2.94M | 0.03 | |
| Renaissance Technologies | $6.68M | 1.74 | 3.65M | -23.59% | -$2.06M | 0.01 | |
| Millennium Management LLC | $5.98M | 1.56 | 3.27M | +25.62% | +$1.22M | <0.01 | |
| BlackRock | $4.65M | 1.21 | 2.54M | -18.69% | -$1.07M | <0.0001 | |
| Qube Research & Technologies | $4.14M | 1.08 | 2.26M | +779.83% | +$3.67M | 0.01 | |
| Geode Capital Management | $3.33M | 0.87 | 1.82M | +0.96% | +$31,587.79 | <0.0001 | |
| Susquehanna International Group | $3.23M | 0.84 | 1.76M | -18.38% | -$726,418.36 | <0.01 | |
| Jacobs Levy Equity Management | $3M | 0.78 | 1.64M | -11.81% | -$401,405.04 | 0.01 | |
| Goldman Sachs | $2.59M | 0.67 | 1.41M | +1,885.44% | +$2.46M | <0.0001 | |
| Connor Clark & Lunn Investment Management Ltd | $1.91M | 0.5 | 1.04M | +68.38% | +$776,198.19 | <0.01 | |
| Marshall Wace | $1.87M | 0.49 | 1.02M | New | +$1.87M | <0.01 | |
| Federated Hermes | $1.59M | 0.41 | 866,554 | 0% | +$0 | <0.01 | |
| Assenagon Asset Management S.A. | $1.45M | 0.38 | 790,483 | New | +$1.45M | <0.01 | |
| Morgan Stanley | $1.44M | 0.38 | 788,375 | +17.01% | +$209,710.79 | <0.0001 | |
| State Street | $1.19M | 0.31 | 650,350 | +6.52% | +$72,834.03 | <0.0001 | |
| Fidelity Investments | $920,937.00 | 0.24 | 503,244 | -13.16% | -$139,530.25 | <0.0001 | |
| Eam Investors | $784,245.00 | 0.2 | 428,549 | New | +$784,245.00 | 0.05 | |
| Jane Street Capital | $728,450.00 | 0.19 | 398,060 | +308.09% | +$549,946.26 | <0.01 | |
| Cubist Systematic Strategies | $728,792.00 | 0.19 | 398,247 | +488.89% | +$605,034.59 | 0.01 | |
| Bank of America | $650,485.00 | 0.17 | 355,456 | +59.53% | +$242,725.90 | <0.0001 | |
| Northern Trust | $611,537.00 | 0.16 | 334,173 | +7.67% | +$43,563.18 | <0.0001 | |
| Marathon Trading Investment Management Llc | $475,802.00 | 0.12 | 260,001 | New | +$475,802.00 | 0.1 | |
| Squarepoint Ops LLC | $466,035.00 | 0.12 | 254,664 | +733.43% | +$410,117.53 | <0.01 | |
| Barclays | $384,000.00 | 0.1 | 210,000 | New | +$384,000.00 | <0.0001 | |
| Citigroup | $343,720.00 | 0.09 | 187,825 | -38.54% | -$215,539.39 | <0.0001 | |
| Point72 Asia Singapore Pte Ltd | $340,805.00 | 0.09 | 186,232 | New | +$340,805.00 | 0.03 | |
| Balyasny Asset Management Llc | $327,191.00 | 0.09 | 178,793 | New | +$327,191.00 | <0.01 | |
| Russell Investments Group Ltd | $321,717.00 | 0.08 | 175,802 | -3.44% | -$11,453.95 | <0.0001 | |
| Two Sigma Advisers LP | $292,707.00 | 0.08 | 159,949 | -4.19% | -$12,810.01 | <0.0001 | |
| Tudor Investment Corp Et Al | $260,361.00 | 0.07 | 142,274 | 0% | +$0 | <0.01 | |
| Y Intercept Hong Kong Ltd | $257,893.00 | 0.07 | 140,925 | New | +$257,893.00 | 0.02 | |
| ExodusPoint Capital Management, LP | $252,000.00 | 0.07 | 137,742 | -43.31% | -$192,522.72 | <0.01 | |
| Creative Planning | $202,563.00 | 0.05 | 110,690 | 0% | +$0 | <0.0001 | |
| Orchard Capital Managment Llc | $198,482.00 | 0.05 | 108,460 | +24.92% | +$39,590.26 | 0.06 | |
| UBS | $181,789.00 | 0.05 | 99,338 | -36.74% | -$105,576.63 | <0.0001 | |
| Dz Bank Ag Deutsche Zentral Genossenschafts Bank Frankfurt Am Main | $169,373.00 | 0.04 | 92,554 | New | +$169,373.00 | <0.0001 | |
| Citadel Advisors LLC | $152,318.00 | 0.04 | 83,234 | -55.87% | -$192,808.52 | <0.0001 | |
| Brevan Howard Capital Management Lp | $149,467.00 | 0.04 | 81,676 | New | +$149,467.00 | 0.01 | |
| Charles Schwab | $146,041.00 | 0.04 | 79,804 | 0% | +$0 | <0.0001 | |
| OMERS | $140,910.00 | 0.04 | 77,000 | New | +$140,910.00 | <0.01 | |
| Hightower Advisors | $135,000.00 | 0.04 | 73,350 | -23.87% | -$42,331.29 | <0.0001 | |
| Bank of Montreal | $125,994.00 | 0.03 | 68,475 | New | +$125,994.00 | <0.0001 | |
| T. Rowe Price | $110,000.00 | 0.03 | 59,900 | 0% | +$0 | <0.0001 | |
| Edmond De Rothschild Holding S A | $91,500.00 | 0.02 | 50,000 | 0% | +$0 | <0.0001 | |
| Cwa Asset Management Group Llc | $89,670.00 | 0.02 | 49,000 | 0% | +$0 | 0.01 | |
| Deerfield Management | $86,193.00 | 0.02 | 47,100 | New | +$86,193.00 | <0.0001 | |
| LMR PARTNERS LLP | $81,761.00 | 0.02 | 44,678 | New | +$81,761.00 | <0.01 | |
| LAZARD ASSET MANAGEMENT LLC | $79,000.00 | 0.02 | 43,545 | New | +$79,000.00 | <0.0001 |